Medical research is conducted with the overarching goal of improving people’s lives. But the value of research isn’t fully realized until research teams translate the science into treatment and care.
Innovation in health care can take the form of a giant leap, a series of small refinements or a combination of the two. But innovation is always the product of collaboration and strong relationships and in this case, was helped along by a chance meeting in the hallway of a conference facility in Vienna.
The health needs of Atlantic Canadians are evolving and Nova Scotia Health has recognized the transformative power of our innovative community and their ability to accelerate the pace of change.
Atrial Fibrillation (Afib) is the most common type of heart rhythm disorders – affecting 200,000 Canadians, and causing one in four strokes after the age of 40.
Collaboration is at the heart of all of our research and Nova Scotia Health is working to expand both research and innovation initiatives across the province.
On March 22, 2020 when the Province of Nova Scotia declared a state of emergency to address the global pandemic, it was clear that COVID-19 was a concern for Nova Scotians.
Health Canada’s investment through its Organ Donation and Transplantation Collaborative, whose mandate is to help make transformative changes in organ donation and transplantation systems across Canada, has awarded $1.1 million to Nova Scotia Health, in collaboration with its key partners including: Nova Scotia Department of Health and Wellness, Canadian Donation and Transplant Research Program, Transplant Québec, and Canadian Blood Services. The purpose of the study is to gather evidence to inform legislative strategies to improve donation and to rigorously evaluate the impact of the overall implementation.
CO-VIC, the COVID-19 treatment and immunity study, will evaluate effectiveness of treatments for hospitalized patients suffering moderate to severe COVID-19 symptoms, while helping researchers discover more about immunity to the virus.
